AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00767988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Urex-cap-5 (2x10^9 cfu each of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1)
Description: Capsules once daily at approximately the same time each day for 6 months.
Study NCT00767988 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule once daily at approximately the same time each day for 6 months.
Study NCT04596384 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Participate in a surgeon-only perioperative care program
Study NCT04596384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Assessment
Description: Complete a functional assessment
Study NCT04596384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear an actigraph
Study NCT04596384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nutritional Assessment
Description: Complete a nutritional assessment
Study NCT04596384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04596384 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04596384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05871255 — intervention group
Intervention type: OTHER
Intervention: Zantogin® Gel
Description: Zantogin® Gel (ZG) is a multicomponent vaginal lubricant endowed with lenitive and anti-inflammatory properties, developed as class II medical device for the treatment of VVA.
Study NCT05467683 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exposure-Based Therapy
Description: Treatment will consist of 12 one-hour sessions, delivered over the course of 12 weeks. EBT will be delivered by trained and experienced license-eligible clinicians. The study clinician will develop a personalized assessment and treatment plan for each patient. Consistent with contemporary models of EBT, exposure practice aims to help patients reestablish a sense of safety around feared cues. Hence, exposure exercises are planned to ensure violation of threat expectancies. That is, exposure practice is deemed appropriate and effective if it allows the patient to learn that what they feared would happen does not happen. Practice will occur across relevant contexts both within and outside the session (i.e., homework) and clinicians will guide patients in processing practice to facilitate the consolidation of safety learning. To achieve these ends, study clinicians will use the manual Personalized Exposure Therapy: A Person-Centered Transdiagnostic Approach.
Study NCT05864001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAR-C mobile app
Description: Digital coaching intervention for healthy lifestyle
Study NCT06074991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: musıc therapy
Description: Music therapy was applied to the patients in the experimental group with the help of mp3 and headphones for 30 minutes in a position where they felt comfortable. Hüseyni makam was used for music therapy.
Study NCT06322056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intensive control of SBP and intensive control of LDL-C
Description: Eligible participants would be assigned to a SBP target of less than 120 mmHg and a LDL-C target of less than 70 mg/dL.
Study NCT06322056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intensive control of SBP and standard control of LDL-C
Description: Eligible participants would be assigned to a SBP target of less than 120 mmHg and a LDL-C target of less than 100 mg/dL.
Study NCT06322056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard control of SBP and intensive control of LDL-C
Description: Eligible participants would be assigned to a SBP target of less than 140 mmHg and a LDL-C target of less than 70 mg/dL.
Study NCT06322056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard control of SBP and standard control of LDL-C
Description: Eligible participants would be assigned to a SBP target of less than 140 mmHg and a LDL-C target of less than 100 mg/dL.
Study NCT04144907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phenylalanine intake
Description: Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein-free cookies and 4 labeled amino acid experimental meals.
Study NCT06549556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA)
Description: Brand name: (Colostrum® 500 mg Veg Capsules) capsules per oral / once daily / 60 days duration.
Study NCT06549556 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule / Capsules per oral / once daily / 60 days duration
Study NCT05196425 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Blood sampling
Description: Blood sample for detection of PARP-1 gene and correlate to changes of the optic disc, RNFL and GCC layers of the retina of MS patients
Study NCT05196425 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood sample for detection of PARP-1 gene and correlate to changes of the optic disc, RNFL and GCC layers of the retina of MS patients
Study NCT06447818 — intervention group
Intervention type: OTHER
Intervention: Change in airway markers
Description: Mallampati and cormack lahane scores will be evaluated at the sixth postoperative month
Study NCT04640844 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: measuring the expression and function of lymphocyte A2A receptors.
Study NCT05334017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylometazoline 0,1%
Description: 1 ml of 0,1% xylometazoline diluted with 1 ml of 0,9% isotonic saline solution given as a nasal spray
Study NCT05334017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cocaine 4%
Description: 2 ml of 4% cocaine given as a nasal spray
Study NCT05152927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parathyroid Eye (PTeye)
Description: Intraoperative Tool
Study NCT05043090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: savolitinib
Description: Tablets : 3 × 200 mg tablets once daily
Study NCT05043090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Concentrate for solution for IV infusion : 1500 mg durvalumab every 4 weeks
Study NCT05043090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sunitinib
Description: Capsules : 2 x 25mg capsules once daily 4 weeks on, 2 weeks off
Study NCT04565041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: Presence of an image of a social support figure (provided by participant) during a fear extinction procedure
Study NCT05054595 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pain Management
Description: Nurses will provide psychoeducation about pain along with common pain coping strategies, such as rest, ice, and elevation, for use any time they experience intense pain or take pain medication before and after surgery.
Study NCT05054595 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audio-Recorded Mindfulness-Based Intervention
Description: Nurses will read patients a brief (1 minute) scripted, introduction to mindfulness and then have them listen to a very brief (1 minute 30 second) guided mindfulness practice validated in our prior research to encourage focused attention on breath and body sensations and open monitoring and acceptance of discursive thoughts, negative emotions, and pain. Finally, patients will be given an audio recording of the mindful pain management technique for use any time.
Study NCT05054595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-Led Mindfulness-Based Intervention
Description: Nurses will read patients a brief (1 minute) scripted, introduction to mindfulness and then guide them through a very brief (1 minute 30 second) mindfulness practice validated in our prior research to encourage focused attention on breath and body sensations and open monitoring and acceptance of discursive thoughts, negative emotions, and pain. Finally, patients will be given an audio recording of the mindful pain management technique for use any time.
Study NCT04977310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioMEMS
Description: Cardio-MEMS-guided Post-LVAD cardiac unloading and recovery
Study NCT06425484 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral US TAP block
Description: epidural plus bilateral US guided TAP block
Study NCT06425484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral US TAP block
Description: epidural plus bilateral US guided TAP block
Study NCT06141044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Avoid surgical drainage
Description: Patients who undergo distal pancreatectomy, avoid placing a drain.
Study NCT05713188 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediSieve Magnetic Haemofiltration System
Description: The MediSieve Magnetic Haemofiltration System is a medical device intended for use in extracorporeal clinical procedures to remove magnetic targets (e.g. malaria infected red blood cells) from a patient's bloodstream. Healthy volunteers will undergo filtration for 5 hours.
Study NCT06219070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core straining
Description: The experimental group received 12 weeks of core training, and the control group received 12 weeks of conventional training, 3 times/times Of the week. Each session lasts 60 minutes and includes warm-up, exercise, and relaxation.
Study NCT05912387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 20 mg tablet once daily by mouth
Study NCT05580744 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional occupational therapy
Description: Motor training targeted to goals that are relevant to the functional needs of the patient
Study NCT05580744 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mirror therapy using a mirror box
Description: Mirror therapy using a mirror box
Study NCT05580744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented reality-based mirror therapy
Description: Augmented reality-based mirror therapy
Study NCT04633707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: adjunctive bright white light therapy in the morning
Description: the participants would receive adjunctive bright white light therapy in the morning (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period: 7:00\~9:00) for 6 weeks.
Study NCT04633707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: adjunctive bright white light therapy in the afternoon
Description: the participants would receive adjunctive bright white light therapy in the afternoon (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period: 12:00\~14:00) for 6 weeks.
Study NCT04633707 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: adjunctive dim red light therapy in the afternoon
Description: the participants received dim red light therapy (light intensity: \<100lux, color: dark red, duration of each intervention session: 30min, time period: 12:00\~14:00) for 6 weeks.
Study NCT05546554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: 5 mg (and up to 20 mg) Suvorexant given orally
Study NCT05546554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo given orally
Study NCT05103228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin Alfa
Description: lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
Study NCT05103228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin delta
Description: lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
Study NCT05103228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human menopausal gonadotropin
Description: lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
Study NCT05474586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collavant n2 40 mg/day
Description: 2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
Study NCT05474586 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine hydrochloride & Chondroitin sulfate
Description: 2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
Study NCT05474586 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline cellulose
Description: 2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
Study NCT05508750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Infant Formula
Description: New infant formula fed daily ad libitum
Study NCT05508750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercial Infant Formula
Description: Commercially available infant formula fed daily ad libitum
Study NCT05227157 — intervention group
Intervention type: OTHER
Intervention: swab with iron sulfate solution
Description: measurement of the intensity of perception of metallic taste by affixing a swab iron sulfate solution 10g/l at 4 places on the tongue depending on the glossopharyngeal nerve: tip of the tongue (right and left); base of the tongue (right and left). Visual analogic Scale (0 to 5)
Study NCT05398510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-2010 injection
Description: Treatment for intravenously: 6 subjects for SR-2010 injection. Treatment for subcutaneously: 8 subjects for SR-2010 injection.
Study NCT05398510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR-2010 injection placebo
Description: Treatment for intravenously: 2 subjects for placebo. Treatment for subcutaneously: 2 subjects for placebo.
Study NCT04179448 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SAMRI
Description: Side Access Mucosal Releasing Incision (SAMRI) will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
Study NCT04179448 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: STA
Description: Sulcular tunnel access incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
Study NCT04924504 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: No interventions
Study NCT05886582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine Transdermal System [Neupro]
Description: Neupro® 2mg/24h transdermal patches for the first seven days, followed by the target 4mg dose for the subsequent 35 days (five weeks) of dosing up to the follow-up assessments, followed by two days of 2mg/24h ramp-down dose.
Study NCT05886582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug
Study NCT05045326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation program
Description: Participants will receive intensive treatment for smoking cessation during day hospital admission.~The intervention is carried out individually and in an open-ended group. The treatment, provided by trained and multidisciplinary professionals (nursing, psychiatry, psychologist, occupational therapist, social work), includes psychological, psycho-educational support, and pharmacological treatment advice.~The group intervention takes place once a week and is divided into six structured sessions that are repeated. Sessions include nicotine addiction and withdrawal, health consequences, benefits of quitting, motivation for change, triggers, coping responses, social support, decision making, pharmacological treatment advice and healthy lifestyle habits.
Study NCT05045326 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Brief Counselling
Description: Participants will receive brief counseling on smoking cessation during their hospital stay. This brief intervention is based on motivational techniques to increase motivation to reduce tobacco use or to initiate treatment.
Study NCT04741386 — intervention group
Intervention type: BIOLOGICAL
Intervention: SARS-CoV-2 vaccination
Description: All participants will receive two vaccinations against COVID-19 according to the manufacturer's instructions.
Study NCT05964998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Current will increase to 1.5 milliamps within 30 seconds and then maintain for 20 minutes
Study NCT05964998 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: Current will increase up to 1.5 milliamps within 30 seconds and then decrease back down over the next 30 seconds to 0 milliamps; subjects will received 0 milliamps for 20 minutes
Study NCT05614661 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mom Power
Description: Experimental participants will receive virtual Mom Power via phone/internet connection. Control participants will receive mail information and confirmation phone calls.
Study NCT05614661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mom Power
Description: Experimental participants will receive virtual Mom Power via phone/internet connection. Control participants will receive mail information and confirmation phone calls.
Study NCT06288945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Program
Description: The educational program included information about definition and causes of Dry eye syndrome (DES), symptoms of DES, diagnostic measures of DES, differentiation between DES and eye allergy, complications of DES, the effect of DES on vision, management of DES, health education about proper eyelid hygiene, proper nutrition to improve the quality of tear film, measures, and precautions to prevent DES such as avoiding exposure to smoke and environmental changes, avoiding prolonged periods in air-conditioned environments; limiting contact lens use to shorter periods, avoiding staring at the computer screen or smartphone for long periods, and taking frequent breaks. In addition, health education about the importance of compliance with the treatment of DES, and instructions to maintain normal eye and vision in patients with DES.
Study NCT04989699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OTX-TKI/Sham
Description: OTX-TKI is one dose so subsequent visits will be sham to maintain the mask
Study NCT04989699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept/Sham
Description: Aflibercept administered every 8 weeks
Study NCT06242054 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Motor Function Assessment System
Description: Participants were instructed to extend their fingers and subsequently clench their fists to the maximum possible range of motion, in order to complete the evaluation of Motor Function Assessment System.
Study NCT06242054 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Motor Function Assessment System
Description: Participants were instructed to extend their fingers and subsequently clench their fists to the maximum possible range of motion, in order to complete the evaluation of Motor Function Assessment System.
Study NCT05212896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC006
Description: BC006 monoclonal antibody injection
Study NCT06493487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated neuromuscular inhibition technique
Description: integrated neuromuscular inhibition technique for gastrocniemus muscle
Study NCT06493487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instrument assissted soft tissue mobilization
Description: instrument assissted soft tissue mobilization for calf muscle
Study NCT06493487 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: convential treatment
Description: convential treatment (home education program, therapeutic ultrasound, plantar fascia stretching, intrinsic muscle strengthening of foot, Self stretching of calf muscle using a towel and Ice Massage using frozen bottle).
Study NCT06393790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FMG (Fibromyalgia group)
Description: This intervention will report results of a strength training programme in people with fibromyalgia
Study NCT06393790 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HG (Healthy group)
Description: This intervention will report results of a strength training programme in people with no fibromyalgia diagnosis
Study NCT04828083 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lidocaine IV
Description: Intravenous lidocaine of 1.5 mg/kg bolus followed by a 1.5 mg/kg/h infusion continuing to the end of phase 1 of post anesthesia care unit
Study NCT04596384 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04596384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TapCloud
Description: Use TapCloud app